The feature describes how Mucocort has applied this approach to develop a mucoadhesive patch for recurrent aphthous stomatitis (RAS), while also highlighting how the same innovation model has given rise to MucoShield.
“We are pleased that Scientia Global has recognised our work,” says Jean Lycke, Project Leader at Mucocort AB. “The article allows us to highlight both the scientific progress behind Mucocort and MucoShield and the innovation strategy that guides our development. We hope it will inspire others by showing that meaningful medical innovation does not always require starting from scratch.”
According to Lycke, the most important takeaway from the article is that innovation can be accelerated by building on established science and focusing on practical solutions.
“Our Close-to-Market approach demonstrates how existing compounds with known safety profiles can be developed into new therapies more efficiently. Scientific excellence and commercial viability are not opposing goals – together, they can help bring new treatments to patients faster and more cost-effectively.”
Read the full article in Scientia Global: LINK
Both Mucocort and MucoShield receive business development support from Umeå Biotech Incubator (UBI).